[go: up one dir, main page]

ATE452880T1 - 2-AMINONICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS - Google Patents

2-AMINONICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS

Info

Publication number
ATE452880T1
ATE452880T1 AT01946854T AT01946854T ATE452880T1 AT E452880 T1 ATE452880 T1 AT E452880T1 AT 01946854 T AT01946854 T AT 01946854T AT 01946854 T AT01946854 T AT 01946854T AT E452880 T1 ATE452880 T1 AT E452880T1
Authority
AT
Austria
Prior art keywords
group
mono
tyrosine kinase
receptor tyrosine
independently
Prior art date
Application number
AT01946854T
Other languages
German (de)
Inventor
Paul Manley
Guido Bold
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE452880T1 publication Critical patent/ATE452880T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to the use of 2-amino-nicotinamide derivatives of formula I wherein n is from 1 up to and including 6; W is O or S; R 1 and R 3 represent independently of each other hydrogen, lower alkyl or lower acyl; R 2 represents a cycloalkyl group, an aryl group, or a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms and 0, 1 or 2 heteroatoms independently from each other selected from the group consisting of oxygen and sulfur, which groups in each case are unsubstituted or mono- or polysubstituted; R and R' are independently of each other hydrogen or lower alkyl; X represents an aryl group, or a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms and 0, 1 or 2 heteroatoms independently from each other selected from the group consisting of oxygen and sulfur, which groups in each case are unsubstituted or mono- or polysubstituted; or a N-oxide, a possible tautomer thereof or a pharmaceutically acceptable salt of such a compound, alone or in combination with one or more other pharmaceutically active compounds for the preparation of a pharmaceutical composition for use for therapy of a disease which responds to an inhibition of the VEGF-receptor tyrosine kinase activity; and to new 2-amino-nicotinamide derivatives of formula I and processes for the preparation thereof.
AT01946854T 2000-01-27 2001-01-25 2-AMINONICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS ATE452880T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0001930.7A GB0001930D0 (en) 2000-01-27 2000-01-27 Organic compounds
PCT/EP2001/000835 WO2001055114A1 (en) 2000-01-27 2001-01-25 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE452880T1 true ATE452880T1 (en) 2010-01-15

Family

ID=9884488

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01946854T ATE452880T1 (en) 2000-01-27 2001-01-25 2-AMINONICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS

Country Status (24)

Country Link
US (1) US6624174B2 (en)
EP (2) EP2168948B1 (en)
JP (1) JP3894793B2 (en)
KR (1) KR100554988B1 (en)
CN (1) CN1216867C (en)
AT (1) ATE452880T1 (en)
AU (1) AU771626B2 (en)
BR (1) BR0107805A (en)
CA (1) CA2396590C (en)
CZ (1) CZ20022582A3 (en)
DE (1) DE60140860D1 (en)
ES (2) ES2490191T3 (en)
GB (1) GB0001930D0 (en)
HU (1) HUP0204083A3 (en)
IL (2) IL150481A0 (en)
MX (1) MXPA02007319A (en)
NO (1) NO323826B1 (en)
NZ (1) NZ520005A (en)
PL (1) PL356307A1 (en)
PT (2) PT1259487E (en)
RU (1) RU2296124C2 (en)
SK (1) SK287426B6 (en)
WO (1) WO2001055114A1 (en)
ZA (1) ZA200205988B (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
US7419428B2 (en) * 2000-04-28 2008-09-02 Igt Cashless transaction clearinghouse
DE10023492A1 (en) * 2000-05-09 2001-11-22 Schering Ag New 2-(((hetero)aryl-alkyl)-amino)-aza-benzamide derivatives, are VEGF receptor, KDR kinase and FLT kinase inhibitors useful e.g. for treating tumors, psoriasis, arthritis or renal or ophthalmological diseases
PT1313734E (en) 2000-09-01 2010-02-09 Novartis Vaccines & Diagnostic Aza heterocyclic derivatives and their therapeutic use
ATE309996T1 (en) 2000-09-11 2005-12-15 Chiron Corp QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS
US20020147198A1 (en) * 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US20030134836A1 (en) * 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
PL364478A1 (en) * 2001-05-08 2004-12-13 Schering Aktiengesellschaft Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
RU2005105683A (en) * 2002-07-31 2006-01-20 Шеринг Акциенгезельшафт (De) POSSESSING INHIBITING ACTION ON VEGFR-2 AND VEGFR-3 ANTHRANILAMIDOPYRIDINES
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
EP1539754A4 (en) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOLE QUINOLINONES AND USES THEREOF
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
GB0229022D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic Compounds
EP2527326B1 (en) 2003-03-07 2014-10-08 Santen Pharmaceutical Co., Ltd Novel compounds having 4-pyridylalkylthio group as substituent
US7129252B2 (en) * 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
CN1856327A (en) * 2003-09-23 2006-11-01 诺瓦提斯公司 Combination of a VEGF receptor inhibitor with a chemotherapeutic agent
EP1667721A2 (en) * 2003-09-23 2006-06-14 Novartis AG Combinations of a vegf receptor inhibitor with other therapeutic agents
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
WO2005046590A2 (en) 2003-11-07 2005-05-26 Chiron Corporation Methods for synthesizing quinolinone compounds
UA89035C2 (en) 2003-12-03 2009-12-25 Лео Фарма А/С Hydroxamic acid esters and pharmaceutical use thereof
PT1717229E (en) 2004-02-17 2011-09-12 Santen Pharmaceutical Co Ltd Novel cyclic compound having 4-pyridylalkylthio group having (un)substituted amino introduced therein
DE102004009238A1 (en) * 2004-02-26 2005-09-08 Merck Patent Gmbh New aryl amide compounds are kinase inhibitors useful for the treatment and/or prophylaxis of e.g. tumors, psoriasis, rheumatoid arthritis, contact dermatitis, inflammations, endometriosis, scar and benign prostatic hyperplasia
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US7507748B2 (en) 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
EP1657241A1 (en) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
EP1655295A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
WO2006070878A1 (en) * 2004-12-28 2006-07-06 Astellas Pharma Inc. Carboxylic acid derivative or salt thereof
EP2410044B1 (en) 2004-12-29 2022-06-22 Hadasit Medical Research Services And Development Ltd. Stem cells culture systems
US8597947B2 (en) 2004-12-29 2013-12-03 Hadasit Medical Research Services & Development Limited Undifferentiated stem cell culture systems
EP1854787B1 (en) 2005-03-03 2010-09-01 Santen Pharmaceutical Co., Ltd. Novel cyclic compound having quinolylalkylthio group
WO2006106914A1 (en) 2005-03-31 2006-10-12 Santen Pharmaceutical Co., Ltd. Novel cyclic compound having pyrimidinylalkylthio group
PL1888556T3 (en) 2005-05-17 2012-03-30 Novartis Ag Methods for synthesizing heterocyclic compounds
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
RU2433826C2 (en) 2005-11-29 2011-11-20 Новартис Аг Compositions of quinolinones
AR059066A1 (en) * 2006-01-27 2008-03-12 Amgen Inc COMBINATIONS OF THE ANGIOPOYETINE INHIBITOR -2 (ANG2) AND THE VASCULAR ENDOTELIAL GROWTH FACTOR INHIBITOR (VEGF)
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
US8063034B2 (en) 2007-01-29 2011-11-22 Santen Pharmaceutical Co., Ltd. Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity
CN103555654B (en) 2007-04-18 2016-04-20 哈达锡特医学研究服务及发展有限公司 Stem cell-derived retinal pigment epithelium
WO2009089271A1 (en) * 2008-01-07 2009-07-16 Ortho-Clinical Diagnostics, Inc. Calibrator/control for simultaneous assay of proteins capable of complexing with one another
CA2717948C (en) * 2008-03-26 2016-09-06 Novartis Ag 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
DK2346827T3 (en) 2008-08-27 2014-02-03 Leo Pharma As Pyridine derivatives such as VEGFR-2 receptor and protein tyrosine kinase inhibitors
CN101676267B (en) * 2008-09-16 2012-12-26 江苏恒瑞医药股份有限公司 N-4-(1-cyan cyclopentyl) phenyl-2-(4-picolyl) amidogen-3-pyridinecarboxamide salt
KR20120093867A (en) 2009-09-10 2012-08-23 아이알엠 엘엘씨 Ether derivatives of bicyclic heteroaryls
WO2011044157A1 (en) * 2009-10-06 2011-04-14 Biogen Idec Ma Inc. Heterocyclic compounds useful as pdk1 inhibitors
WO2011064211A1 (en) 2009-11-25 2011-06-03 Novartis Ag Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
JP2013532149A (en) 2010-06-17 2013-08-15 ノバルティス アーゲー Piperidinyl-substituted 1,3-dihydro-benzimidazol-2-ylideneamine derivatives
WO2011157787A1 (en) 2010-06-17 2011-12-22 Novartis Ag Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
JP2014507465A (en) 2011-03-08 2014-03-27 ノバルティス アーゲー Fluorophenyl bicyclic heteroaryl compounds
KR101412794B1 (en) * 2011-07-27 2014-07-01 보령제약 주식회사 New compound, the preparation thereof and the pharmaceutical composition comprising the same for anti-angiogenic drug
EP2846803B1 (en) * 2012-05-08 2017-06-21 Alpharmagen, LLC Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
PL3074038T3 (en) 2013-11-28 2019-08-30 Csl Limited Method of treating diabetic nephropathy
US10016398B2 (en) 2014-02-21 2018-07-10 Frost Biologic, Inc. Antimitotic amides for the treatment of cancer and proliferative disorders
IL321407A (en) 2014-12-30 2025-08-01 Cell Cure Neurosciences Ltd Rpe cell populations and methods of generating same
CA2972580A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
US11230696B2 (en) 2015-07-29 2022-01-25 Hadasit Medical Research Services And Development Ltd. Large scale production of retinal pigment epithelial cells
EP3331995A1 (en) 2015-08-05 2018-06-13 Cell Cure Neurosciences Ltd. Preparation of photoreceptors for the treatment of retinal diseases
AU2016303632B2 (en) 2015-08-05 2022-09-29 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
CN108368083B (en) 2015-08-31 2022-02-01 东亚首希控股股份有限公司 Heteroaryl compounds and their use as therapeutic agents
EP4545633A3 (en) 2015-10-26 2025-07-09 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
IL268357B2 (en) 2017-02-08 2025-07-01 Hadasit Med Res Service Photoreceptor cells for the treatment of retinal diseases
WO2018170494A1 (en) 2017-03-16 2018-09-20 Bio Time, Inc. Methods for measuring therapeutic effects of retinal disease therapies
EP3697425A1 (en) 2017-10-18 2020-08-26 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Methods and compounds for improved immune cell therapy
WO2019119486A1 (en) 2017-12-21 2019-06-27 中国科学院合肥物质科学研究院 Class of pyrimidine derivative kinase inhibitors
WO2020058979A2 (en) 2018-09-20 2020-03-26 Yeda Research And Development Co. Ltd. Methods of treating amyotrophic lateral sclerosis
EP3754014A1 (en) 2019-06-21 2020-12-23 Centre d'Etude des Cellules Souches (CECS) Automated method for preparing retinal pigment epithelium cells
EP4058465A1 (en) 2019-11-14 2022-09-21 Cohbar Inc. Cxcr4 antagonist peptides
EP4351334A1 (en) 2021-06-09 2024-04-17 Lineage Cell Therapeutics, Inc. Methods and compositions for treating retinal diseases and conditions
CN117957311A (en) 2021-07-28 2024-04-30 谱系细胞疗法公司 Expansion of retinal pigment epithelial cells
WO2023211857A1 (en) 2022-04-25 2023-11-02 Lineage Cell Therapeutics, Inc. Methods and compositions for treating vision loss

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2058656T3 (en) * 1989-04-20 1994-11-01 Boehringer Ingelheim Pharma 5,11-DIHIDRO-6H-DIPIRIDO (3,2-B: 2 ', 3'-E) (1,4) DIAZEPIN-6-ONAS AND ITS USE IN THE PREVENTION OR TREATMENT OF AIDS.
AU691834B2 (en) * 1993-10-01 1998-05-28 Novartis Ag Pharmacologically active pyridine derivatives and processes for the preparation thereof
DE69738468T2 (en) * 1996-08-23 2009-01-08 Novartis Ag SUBSTITUTED PYRROLOPYRIMIDINES AND METHOD FOR THE PRODUCTION THEREOF
CN1254335A (en) 1997-04-04 2000-05-24 辉瑞产品公司 Nicotinamide derivatives
AU8033598A (en) 1997-06-18 1999-01-04 Nissan Chemical Industries Ltd. Pyridine compounds and herbicides
AR013693A1 (en) 1997-10-23 2001-01-10 Uriach & Cia Sa J NEW PIPERIDINES AND PIPERAZINAS AS INHIBITORS OF THE PLAQUETARY AGREGATION
WO1999062885A1 (en) * 1998-06-05 1999-12-09 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
DE69931393T2 (en) 1998-12-23 2007-03-29 Eli Lilly And Co., Indianapolis ANTITHROMBOTIC AMIDE
PT1169038E (en) * 1999-04-15 2012-10-26 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
CA2397493A1 (en) 2000-01-27 2001-08-02 Cytovia, Inc. Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof

Also Published As

Publication number Publication date
HUP0204083A2 (en) 2003-03-28
CA2396590C (en) 2011-03-01
PT1259487E (en) 2010-03-26
EP1259487A1 (en) 2002-11-27
ES2338407T3 (en) 2010-05-07
CN1216867C (en) 2005-08-31
SK10852002A3 (en) 2003-05-02
ZA200205988B (en) 2003-07-28
CZ20022582A3 (en) 2002-10-16
US6624174B2 (en) 2003-09-23
JP3894793B2 (en) 2007-03-22
WO2001055114A1 (en) 2001-08-02
IL150481A (en) 2009-09-22
EP2168948B1 (en) 2014-05-07
NZ520005A (en) 2004-02-27
GB0001930D0 (en) 2000-03-22
AU771626B2 (en) 2004-04-01
NO323826B1 (en) 2007-07-09
DE60140860D1 (en) 2010-02-04
US20030032656A1 (en) 2003-02-13
MXPA02007319A (en) 2002-11-29
SK287426B6 (en) 2010-09-07
KR20020071973A (en) 2002-09-13
KR100554988B1 (en) 2006-02-24
NO20023218D0 (en) 2002-07-02
EP1259487B8 (en) 2014-04-23
CA2396590A1 (en) 2001-08-02
EP2168948A1 (en) 2010-03-31
HK1050895A1 (en) 2003-07-11
CN1396912A (en) 2003-02-12
AU2849901A (en) 2001-08-07
EP1259487B1 (en) 2009-12-23
PL356307A1 (en) 2004-06-28
PT2168948E (en) 2014-08-26
HUP0204083A3 (en) 2005-03-29
BR0107805A (en) 2002-10-22
RU2296124C2 (en) 2007-03-27
JP2003520853A (en) 2003-07-08
ES2490191T3 (en) 2014-09-03
IL150481A0 (en) 2002-12-01
NO20023218L (en) 2002-09-16

Similar Documents

Publication Publication Date Title
DE60140860D1 (en) 2-AMINONICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS
ATE180468T1 (en) ANTHRANILIC ACID DERIVATIVES
MX2007006821A (en) 2,4 (4,6) pyrimidine derivatives.
DE69428476D1 (en) Heterocyclic compounds as bradykinin antagonists
DE69614147D1 (en) CHINAZOLIN DERIVATIVES
DE60140456D1 (en) AZA HETEROCYCLIC DERIVATIVES AND ITS THERAPEUTIC USE
ATE496035T1 (en) NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS
ATE274512T1 (en) PHENYL UREAS AND PHENYLTHIOUREAS AS OREXIN RECEPTOR ANTAGONISTS
EA200601235A1 (en) TIAZOLE DERIVATIVES
ATE247654T1 (en) NEW HETEROCYCLIC COMPOUNDS
EP1396493A4 (en) Heterocyclic compounds
DE60115465D1 (en) IMMUNO-REGULATING COMPOUNDS, DERIVATIVES AND THEIR USE
DE3781080D1 (en) 2-SUBSTITUTED-E-CONDENSED (1,2,4) TRIAZOLO- (1,5-C) PYRIMIDINE, PHARMACEUTICAL PREPARATIONS AND THEIR USE.
EP1061076A4 (en) CYCLIC N-ACYL AMINE DERIVATIVES
NO900542D0 (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE BENZO CONDENSED N-containing HETEROCYCLIC DERIVATIVES.
ATE324890T1 (en) COMPOSITION CONTAINING AN ANGIOTENSIN II RECEPTOR ANTAGONIST AND A DIURETIC AND THE USE THEREOF FOR THE TREATMENT OF HYPERTENSION
TR200103789T2 (en) 1,4-dihydroindeno [1,2-C] pyrazoles substituted as tyrosine kinase inhibitors.
PT1315730E (en) 1 - [(HETEROARYL) -ALQUIL] AND 1 - [(ARYL) -ALQUIL] -7-PYRIDINYL-IMIDAZO [1,2-A] PYRIMIDIN-5 (1H) -ONE DERIVATIVES
DK0780125T3 (en) Use of hydantoin derivatives for the manufacture of a medicament for the treatment of diseases associated with the presence of active oxygen and free radicals
MXPA02011464A (en) 1,4 diazepan 2,5 dione derivatives and their use as nk 1 receptor antagonists.
DE69720966D1 (en) BENZO [C] CHINOLIZINE DERIVATIVES, THE PRODUCTION AND USE THEREOF AS 5-ALFA REDUCTASE INHIBITORS
BR0209332A (en) Phthalazine derivatives with angiogenesis inhibiting activity
NO20022456L (en) Pyrazolo [1,5-d] [1,2,4] triazine derivatives for cognitive enhancement
EA199800720A1 (en) HETEROCYCLIC DERIVATIVES OF ERGOLINE AS 5-HTIA LIGANDS RECEPTOR
CA2385244A1 (en) Novel nicotinonitrile compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1259487

Country of ref document: EP